Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy.
about
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysisMetformin effects on biochemical recurrence and metabolic signaling in the prostate.Diabetes and the risk of biochemical recurrence in patients with treated localized prostate cancer: a meta-analysis.Prostate-specific antigen nadir concentration, hypertension and diabetes as risk factors for biochemical failure after permanent 125I seed brachytherapy for prostate cancer.Effects of metformin treatment on radiotherapy efficacy in patients with cancer and diabetes: a systematic review and meta-analysis
P2860
Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Metformin is not associated wi ...... nt interstitial brachytherapy.
@en
type
label
Metformin is not associated wi ...... nt interstitial brachytherapy.
@en
prefLabel
Metformin is not associated wi ...... nt interstitial brachytherapy.
@en
P2093
P2860
P356
P1476
Metformin is not associated wi ...... nt interstitial brachytherapy.
@en
P2093
Al V Taira
Edward Adamovich
Gregory S Merrick
Mallory Morris
Robert W Galbreath
Wayne M Butler
P2860
P304
P356
10.5114/JCB.2014.45757
P577
2014-10-06T00:00:00Z